InMode (NASDAQ:INMD) Announces Earnings Results

InMode (NASDAQ:INMD) issued its quarterly earnings data on Wednesday. The healthcare company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.32 by $0.05, FiscalAI reports. The business had revenue of $92.14 million for the quarter, compared to the consensus estimate of $91.58 million. InMode had a return on equity of 11.99% and a net margin of 20.69%. The firm’s revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.38 EPS.

InMode Trading Up 1.8%

Shares of InMode stock traded up $0.23 during mid-day trading on Wednesday, reaching $13.50. 420,340 shares of the stock were exchanged, compared to its average volume of 785,534. InMode has a fifty-two week low of $12.72 and a fifty-two week high of $16.67. The firm has a 50-day simple moving average of $14.19 and a 200 day simple moving average of $14.31. The company has a market cap of $776.21 million, a price-to-earnings ratio of 10.98 and a beta of 1.98.

Analyst Ratings Changes

Separately, Weiss Ratings cut InMode from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, InMode has a consensus rating of “Hold” and a consensus target price of $16.00.

InMode Company Profile

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.